SCHEMBL5582701

SCHEMBL5582701

COc1ccc(CC(=O)Nc2ccc(CC(=O)NCCN(C)C)cc2)cc1OC

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 1/20 0.66
BCHE P06276 3/20 0.64
ACHE P22303 3/20 0.64
KDM4E B2RXH2 2/20 0.57
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
NPSR1 Q6W5P4 2/20 0.56
MAPT P10636 2/20 0.55
KMT2A Q03164 2/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
POLB P06746 2/20 0.53
ALDH1A1 P00352 1/20 0.53
HPGD P15428 1/20 0.53
HSD17B10 Q99714 1/20 0.53
RXFP1 Q9HBX9 1/20 0.53
STAT3 P40763 1/20 0.53
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2404899 0.92 L3MBTL1 (0.63) EPHX2BCHEACHENPSR1KMT2A
SCHEMBL19427446 0.80 EPHX2 (0.80) EPHX2BCHEACHEKDM4ESMN1; SMN2
SCHEMBL3653095 0.79 EPHX2 (0.77) EPHX2BCHEACHEKDM4ESMN1; SMN2
SCHEMBL248400 0.77 CA1 (0.79) MAPTKMT2AL3MBTL1CA1CA2
SCHEMBL30738251 0.77 CA1 (0.79) MAPTKMT2AL3MBTL1CA1CA2
SCHEMBL2405624 0.77 L3MBTL1 (0.67) EPHX2KDM4ENPSR1KMT2AL3MBTL1
SCHEMBL5582634 0.76 HTT (0.69) KDM4ESMN1; SMN2LMNAHTTMAPT
SCHEMBL2403698 0.76 L3MBTL1 (0.70) EPHX2KDM4ENPSR1KMT2AL3MBTL1
SCHEMBL5582687 0.76 POLB (0.53) EPHX2SMN1; SMN2LMNAMAPTKMT2A
SCHEMBL27707946 0.75 L3MBTL1 (0.64) EPHX2NPSR1KMT2AL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US claimed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-20070173498-A1 Melanin concentrating hormone antagonist KATO KANEYOSHI 2007-07-26 US disclosed
US-7115750-B1 Melanin concentrating hormone antagonist TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-10-03 US disclosed
EP-1218336-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST Takeda Chemical Industries, Ltd. (JP) 2002-07-03 EP disclosed
WO-2001021577-A2 MELANIN CONCENTRATING HORMONE ANTAGONIST TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173498-A1 Melanin concentrating hormone antagonist MC1R, MCHR1, MCHR2 EPHX2 3752/4885BCHE 4748/4885ACHE 4858/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.